Multiple Sclerosis
Conference Coverage
sNFl and sGFAP Predict MS Disability in Unique Ways
GFAP might soon join serum neurofilament light chain (sNFl) levels for predicting disability, but each has unique features and they appear to...
Conference Coverage
McDonald Criteria Update Aims to Simplify, Speed MS Diagnosis
Significant changes to the diagnostic criteria of MS have been proposed. The next steps will include consulting with the wider MS community and...
Conference Coverage
Genetically Driven Depression Tied to Increased MS Disease Activity
This study increases awareness of the link between depression and MS.
Conference Coverage
Ofatumumab MS Study Supports Early Start Over Switch
New extension data from phase 3 ofatumumab RRMS study, show lower long-term disability accumulation with early-start of the more potent therapy...
Conference Coverage
Novel Agent First to Slow Disability in Nonrelapsing Secondary MS
The phase 3 HERCULES trial showed tolebrutinib, an oral Bruton’s tyrosine kinase inhibitor, delayed the time to onset of 6-month confirmed...
Conference Coverage
No Signal of Benefit for Simvastatin in Progressive MS
Conference Coverage
Disability Reduction Is a Twist in Negative BTKi RRMS Trial
In phase 3 RRMS trials, tolebrutinib showed no advantage over teriflunomide for a relapse endpoint, but a disability endpoint advantage might...
Conference Coverage
High-Dose Vitamin D Linked to Lower Disease Activity in CIS
The 34% reduction in relative risk for disease activity is “similar to that of some published platform therapies for CIS patients.”
Conference Coverage
Positive Stem Cell Transplant Data Is Increasing Its Use
The growing quantity of real-world data supporting hematopoietic stem cell transplant for MS is driving its growing routine application at centers...
Conference Coverage
Comorbidity Control Might Slow MS Activity